Core Viewpoint - The company, Anglikon (002940), has announced that it currently has only one innovative drug project, ALK-N001, which is in Phase I clinical trials as of the date of the announcement [1] Group 1: Drug Development Status - The only drug project in development is ALK-N001, which is still in Phase I clinical trials [1] - A strategic cooperation agreement regarding the ALK-N002 project was signed with Afei (Shanghai) Biopharmaceutical Technology Co., Ltd. and Shanghai Qinhuali Biopharmaceutical Technology Co., Ltd. on August 26, 2025 [1] - The agreement has been approved by the company's shareholders, and the partners are currently undergoing internal approval processes [1] Group 2: Investor Advisory - The company has issued a reminder to investors to make rational decisions and be aware of investment risks [1]

证券代码：002940 证券简称：昂利康 公告编号：2025-075 浙江昂利康制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）股票（证 券代码：002940，证券简称：昂利康）连续 3 个交易日（2025 年 10 月 15 日、 2025 年 10 月 16 日、2025 年 10 月 17 日）收盘价格涨幅偏离值累计超过 20%， 根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动情况，公司董事会对有关事项进行了核查，有关 情况说明如下： 1、公司前期披露的信息不存在需要更正或补充披露的事项； 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、经核查，公司目前经营情况正常，主营业务未发生变化，内外部经营环 境未发生重大变化； 4、公司及控股股东、实际控制人不存在关于本公司的应披露而未披露的重 大事项，也不 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-074 浙江昂利康制药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的左氧氟沙星片《药品注册证书》， 现将有关情况公告如下： | 药品通用名称 | 左氧氟沙星片 | | --- | --- | | 主要成份 | 左氧氟沙星 | | 剂型 | 片剂 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 类 4 | | 规格 | 0.5g（按 C₁₈H₂₀FN₃O₄计） | | 受理号 | CYHS2401067 | | 药品批准文号 | 国药准字 H20255669 | | 药品批准文号有效期 | 至 年 月 日 2030 10 13 | | 上市许可持有人 | 名称：浙江昂利康制药股份有限公司 地址：浙江省嵊州市嵊州大道北 号 1000 | | 生产企业 | 名称：浙江昂利康制药股份有限公司 地址：绍兴市嵊州市嵊州大道北 1000 ...

Core Viewpoint - The company has received a drug registration certificate for Levofloxacin Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Group 1: Product Information - Levofloxacin Tablets are classified as a third-generation fluoroquinolone antibiotic, known for their broad antibacterial spectrum and strong antibacterial action [1] - The drug is intended for the treatment of mild, moderate, and severe infections in adults (≥18 years) caused by specified sensitive strains [1] Group 2: Regulatory Milestones - The company received the notice of acceptance for the drug's marketing authorization application in April 2024, followed by the recent approval [1]

Core Insights - The report maintains a positive outlook on the pharmaceutical and biotechnology sector, highlighting a significant reduction in tariff risks for multinational corporations (MNCs) in the industry due to agreements with the U.S. government [5][8] - MNCs are expected to continue relying heavily on China's supply chain for raw materials and intermediates in the short term, despite the tariff reductions [5][8] - Emerging technologies such as small nucleic acid drugs and in vivo Car-T are maturing, creating new order opportunities for the Chinese supply chain [5][9] Section Summaries MNC Tariff Risk Reduction - The U.S. government has reached agreements with companies like AstraZeneca and Pfizer, allowing them to invest more in U.S. manufacturing and reduce drug prices in exchange for a three-year tariff exemption [5][8] - MNCs will likely adopt similar strategies to mitigate tariff risks, which will significantly lower the overall tariff burden on the industry [5][8] Industry Performance Review - As of October 10, 2025, the TTM-PE for the pharmaceutical and biotechnology sector is 51.48 times, which is 111% higher than the historical low of 24.38 times [10] - The sector's premium over the CSI 300 index is 263%, exceeding the historical low premium by 139 percentage points [10] Subsector Performance - The pharmaceutical and biotechnology sector experienced a decline of 1.20% from September 25 to October 10, 2025, ranking 21st among 27 subsectors [14][17] - Within the sector, traditional Chinese medicine saw an increase of 1.51%, while medical services and chemical preparations faced declines of 3.37% and 2.48%, respectively [17] Individual Stock Performance - The top three performing stocks in the sector were *ST Guohua (10.25%), Changshan Pharmaceutical (8.69%), and Zhenbao Island (8.56%) [21] - Conversely, the worst performers included Furui Co. (-7.47%), Xinlitai (-6.71%), and Jiming Health (-6.50%) [21] Q3 2025 Earnings Forecast - The report provides a detailed earnings forecast for Q3 2025, indicating expected net profits for various companies, including JianKai Technology and MeiNian Health, with specific growth drivers highlighted [23][24] Industry Dynamics - Recent approvals for new drugs and treatments, such as UCB's Zilucoplan for myasthenia gravis and Hemay005 for psoriasis, indicate ongoing innovation and regulatory progress within the sector [25][27][29]

证券代码：002940 证券简称：昂利康 公告编号：2025-073 浙江昂利康制药股份有限公司 特别提示 1、为尊重中小投资者利益，提高中小投资者对公司股东大会审议的重大事 项参与度，本次股东大会审议的部分议案对中小投资者实行单独计票。中小投资 者是指除以下股东以外的其他股东：（1）上市公司的董事、监事、高级管理人员； （2）单独或者合计持有上市公司 5%以上股份的股东； 2、本次股东大会无否决或修改议案情况； 3、本次股东大会没有涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2025 年 10 月 16 日下午 14：30 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 网络投票时间：2025 年 10 月 16 日 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 10 月 16 日上午 9：15 至 9：25，9：30 至 11：30 和下午 13：00 至 15：00； 通过深圳证券交易所互联网投票系统（http://w ...

法律意见书 法律意见书 浙江天册律师事务所 关于浙江昂利康制药股份有限公司 2025 年第一次临时股东大会的 编号：TCYJS2025H1720 致：浙江昂利康制药股份有限公司 根据《中华人民共和国证券法》（下称"《证券法》"）、《中华人民共和国公司法》（下 称"《公司法》"）和《上市公司股东会规则》等法律、法规和规范性文件的要求及《浙 江昂利康制药股份有限公司章程》（下称"《公司章程》"）、《浙江昂利康制药股份有限 公司股东大会议事规则》（下称"《议事规则》"）的规定，浙江天册律师事务所（下称 "本所"）接受浙江昂利康制药股份有限公司（下称"昂利康"或"公司"）的委托，指 派俞晓瑜、郑忻律师（下称"本所律师"）参加昂利康 2025 年第一次临时股东大会，对 本次股东大会的召集和召开程序、出席会议人员资格、表决方式、表决程序的合法性、 有效性进行了认真审查，并出具本法律意见书。 本法律意见书仅供昂利康 2025 年第一次临时股东大会之目的使用。本所律师同意 将本法律意见书随昂利康本次股东大会其他信息披露资料一并公告。 本所律师根据相关法律法规的要求，按照律师行业公认的业务标准、道德规范和勤 勉尽责的精神，出席 ...

Core Viewpoint - The A-share market continues to show strength in innovative drug concept stocks, with significant gains observed across multiple companies on October 16 [1] Group 1: Stock Performance - Guizhou BaiLing and Luoxin Pharmaceutical reached the daily limit up [1] - Yifang Bio increased by over 7% [1] - Laime Pharmaceutical, Guangsheng Tang, Anglikang, and Shutaishen all rose by over 6% [1] - Dize Pharmaceutical and Lianhuan Pharmaceutical saw increases of over 5% [1]

Market Overview - The market showed strong fluctuations throughout the day, with the Shanghai Composite Index returning above 3900 points. The trading volume reached 2.09 trillion yuan, with over 4300 stocks in the Shanghai and Shenzhen markets closing in the green [1]. Key Sectors Robotics - The robotics sector experienced significant gains, with stocks like Yuanda Intelligent, Zhongjian Technology, and Zhenghe Industrial hitting the daily limit. The core stock, Sanhua Intelligent Control, also recorded a limit-up. The market was catalyzed by the emergence of new robotics orders and Tesla's announcement regarding its 2025 shareholder meeting, highlighting the "Fourth Macro Map" robot as a key focus [4][5]. Cloud Computing Data Centers - The cloud computing data center sector saw a notable rise, with stocks such as Jingquanhua, Sifang Co., and Heshun Electric hitting the daily limit. The interest was fueled by Nvidia's recent release of a white paper on the 800VDC architecture, emphasizing the importance of medium-voltage rectifiers for rapid deployment of 800VDC systems [6][7][8]. Pharmaceuticals - The pharmaceutical sector rebounded, with stocks like Angli Kang, Jimin Health, and Lianhuan Pharmaceutical reaching the daily limit. The upcoming European Society for Medical Oncology (ESMO) annual meeting in Berlin is expected to be a significant platform for releasing critical clinical data, drawing attention to the innovative drug sector [10][11]. Notable Stocks - **Robotics**: Yuanda Intelligent (4.30 yuan, +9.97%), Zhongjian Technology (131.98 yuan, +10.00%), Sanhua Intelligent Control (3383.5 million yuan market cap) [5][15]. - **Cloud Computing**: Jingquanhua (23.87 yuan, +10.00%), Sifang Co. (24.88 yuan, +9.99%), Heshun Electric (13.18 yuan, +20.04%) [8][9]. - **Pharmaceuticals**: Angli Kang (41.20 yuan, +10.01%), Jimin Health (10.97 yuan, +10.03%), Lianhuan Pharmaceutical (20.90 yuan, +10.00%) [11][12].

Market Overview - The chemical pharmaceutical sector increased by 2.94% on October 15, with Sunflower leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Notable stock performances in the chemical pharmaceutical sector include: - Sunflower (300111) closed at 8.11, up 19.97% with a trading volume of 3.1035 million shares [1] - Guangshantang (300436) closed at 120.00, up 17.41% with a trading volume of 298,500 shares [1] - Shutaishen (300204) closed at 36.26, up 12.50% with a trading volume of 597,600 shares [1] - Anglikang (002940) closed at 41.20, up 10.01% with a trading volume of 129,600 shares [1] - Lianhuan Pharmaceutical (600513) closed at 20.90, up 10.00% with a trading volume of 309,500 shares [1] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 2.451 billion yuan from institutional investors, while retail investors experienced a net outflow of 948 million yuan [2][3] - The capital flow for key stocks includes: - Sunflower (300111) had a net inflow of 4.41 billion yuan from institutional investors [3] - Guangshantang (300436) had a net inflow of 2.82 billion yuan from institutional investors [3] - Lianhuan Pharmaceutical (600513) had a net inflow of 1.33 billion yuan from institutional investors [3]